Hyzaar

Losartan potassium, the active ingredient in Hyzaar, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often together with a thiazide diuretic, and is prescribed for adults requiring long-term effective blood pressure control.

GNH USA supplies Hyzaar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for global distribution. The company adheres to stringent manufacturing standards and provides comprehensive documentation to meet the requirements of health authorities across regions.

Hyzaar is an antihypertensive combination that lowers blood pressure by targeting the renin‑angiotensin system and reducing fluid volume.

- Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. - Hypertension with fluid retention: provides combined vasodilation and diuresis to manage excess fluid. - Hypertension requiring combination therapy: offers a single tablet that includes both an ARB and a thiazide diuretic for simplified treatment.

Common Side Effects: - Dizziness or light‑headedness - Headache - Increased urination or frequency of urination - Mild electrolyte disturbances such as low potassium - Fatigue or general weakness - Nausea or mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Hyperkalemia or marked changes in potassium levels - Acute kidney injury or worsening renal function - Angioedema or severe allergic reaction - Pancreatitis or severe abdominal pain - Hepatic dysfunction or jaundice

Hyzaar should be used with careful monitoring in several clinical situations. - Renal function monitoring: assess serum creatinine and eGFR before and during therapy. - Electrolyte monitoring: check potassium and sodium levels regularly, especially in patients on other diuretics. - Caution in elderly: start at lower doses and monitor for orthostatic hypotension. - Avoid in severe hepatic impairment: dose adjustment may be required. - Do not combine with other potassium‑sparing agents without supervision. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Hyzaar may interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: risk of renal impairment and hyperkalemia. - Co‑administration with ACE inhibitors or other ARBs: may cause excessive potassium rise and kidney dysfunction. - Use with lithium: increased lithium levels and toxicity. - NSAIDs combined with Hyzaar: heightened risk of renal failure. - Potassium‑sparing diuretics: can precipitate severe hyperkalemia.

Moderate Interactions (Monitor Closely): - Other thiazide diuretics: may amplify electrolyte disturbances. - Beta‑blockers or other antihypertensives: additive blood‑pressure lowering effect. - CYP2C9 inhibitors (e.g., fluconazole): may increase losartan plasma concentrations. - Antidiabetic agents: diuretic‑induced changes in glucose may affect glycemic control. - Anticoagulants: diuretic‑related volume changes can alter drug levels.